Christine Burkett Email

Finance Administrator . Vivaldi Biosciences

Current Roles

Employees:
12
Revenue:
$1.9M
About
Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi's DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.
Vivaldi Biosciences Address
3185-A Rampart Road
Fort Collins, CO
United States
Vivaldi Biosciences Email

Past Companies

Vivaldi Biosciences Inc.Finance Administrator
Peninsula Design SourceCo-Owner
Global BSNDirector of Administration

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.